Why Beam Therapeutics Climbed 64.5% in June
Shares of Beam Therapeutics (NASDAQ: BEAM) jumped almost 65% last month according to S&P Global Market Intelligence. The move was in concert with other gene editing companies after Intellia Therapeutics and Regeneron announced results from a phase 1 study. The data indicated the pair had successfully used CRISPR-Cas9 to treat a rare liver disease.
The trial was the first to show that the gene editing approach could be used directly in the body to treat a disease. The drug, NTLA-2001, was given as a single-dose infusion to treat transthyretin (ATTR) amyloidosis. The breakthrough opens the door for other gene editing therapies and approaches such as Beam's base editing technology.
Image source: Getty Images.
Source Fool.com
